

Sample Received: **April 7, 2026**COA Issued: **April 13, 2026**

## PRODUCT INFORMATION

Vendor: **La Peptides**      Sample Name: **GLP3-R 20mg**      Sample Type: **White lyophilized powder**      Lot Number: **BATCH 1018**      MW: **4731.3 g/mol**

## ANALYTICAL METHODS

**Identity:** Confirmed via MALDI-MS

**Purity:** RP-HPLC (214 nm)


**Content:** HPLC quantitation

## TEST RESULTS


| Specification    | Result      | Method            | Status     |
|------------------|-------------|-------------------|------------|
| Identity: GLP3-R | GLP3-R      | MALDI-MS          | ✓ Conforms |
| Content          | 22.11 mg    | HPLC Quantitation | ✓ Conforms |
| Overall Purity   | 99.8%       | RP-HPLC (214 nm)  | ✓ Conforms |
| Endotoxin        | <0.05 EU/mL | <USP85>           | ✓ Conforms |

## ANALYTICAL DATA

HPLC Chromatogram (Retention Time: 10.3.0 min)



## Mass Spectrum (MALDI-MS)



**Certification:** This COA confirms that the tested material meets or exceeds Bioviridian's analytical quality specifications for peptide research use.

Visit: <https://bioviridians.com/coa-search.html>



*Shane Straight*  
Shane Straight, M.S.  
Principal Chemist, Bioviridian Inc.